[The effectiveness of adjuvant systemic therapy in organ-preserving therapy of breast cancer].
The role of adjuvant therapy in breast-conserving treatment was studied in 360 cancer patients (reproductive, aged < or = 55 yrs, and postmenopausal, aged > 55 yrs) with T1-2N0M0 tumors under 2.5 cm (1985-1996). Mortality rates fell by 17% in postmenopausal patients who received adjuvant therapy (tamoxifen) and by 34%--in the reproductive group after polychemotherapy (CMF) and 36%--after hormonal therapy (tamoxifen).